Alice Tsang Shaw, MD, PhD, and Tony Mok, MD: Results From the ARCHER 1050 Trial

Posted: Thursday, June 15, 2017

Alice Tsang Shaw, MD, PhD, of Massachusetts General Hospital, and Tony Mok, MD, of the Chinese University of Hong Kong, discuss phase III study findings on dacomitinib vs gefitinib for first-line treatment of advanced EGFR mutation–positive non–small cell lung cancer.